GOG GYN-LIVE - INDUSTRY SUPPORTED SYMPOSIA

The GOG Foundation, Inc. and GOG Partners welcome gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to listen to the Evolving Evidence and Treatment Strategies in Platinum Resistant Ovarian Cancer: From Biology to Bedside symposium podcast that was presented at the FSGO 2026 Annual Meeting in Long Boat...

The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to access the Future of ADCs: Accelerating Progress in Ovarian and Endometrial Cancer Enduring Educational Symposium that was presented at the FSGO 2026 Annual Meeting in Long Boat Key, Florida a on Sun...

The GOG Highlight Reel distills practice-changing information disclosed during recent major medical meetings into a two-and-a-half-hour segment. This comprehensive course examines recent clinical trial data in gynecologic malignancies, offering insights on data presentations, ongoing research, and drug approvals shaping the field. It addresses common gynecologic malignancies, aiding physicians in...

This program provides an in‑depth review of the evolving treatment landscape in ovarian cancer with a focus on emerging science and practical application in patient care. Participants will explore the current competitive landscape, new indications, and recent data surrounding folate receptor alpha–targeted therapies. The session will also look ahead to future developments, including the role of an...

Molecular residual disease (MRD) tracking via tumor-informed circulating tumor DNA (ctDNA) is redefining the surveillance and management paradigm in gynecologic oncology. This session delivers a data-driven evaluation of the evolving role of ctDNA in identifying subclinical recurrence and quantifying real-time treatment response across ovarian, uterine, and cervical cancers—frequently months ahead...

Despite advances in ovarian cancer treatment, outcomes for patients with platinum‑resistant disease remains poor, with therapeutic decisions becoming increasingly complex as novel biomarkers and targeted therapies emerge. This 45‑minute case‑based educational program will provide clinicians with practical guidance on integrating folate receptor alpha (FRα) testing into real‑world decision‑making,...

This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease. Faculty will provide expert insights on current treatment paradigms, including immunotherapy, chemotherapy, and novel combinations. Through integrated patient case discussions, the session will highlight how molecular profiling drives...

This course offers a clinically relevant exploration of evolving treatment strategies in ovarian and endometrial cancers for a global audience.  The primary focus of this course will help learners understand how to make biomarker-driven decisions for on-label therapeutic pathways. Learners will deepen their understanding of the role of BRCA, HRD, MMR/MSI, and emerging biomarkers such as p53 for eq...

This interactive 90-minute symposium will explore the evolving treatment landscape in endometrial cancer, focusing on the distinctions between dMMR and pMMR disease. Faculty will provide expert insights on current treatment paradigms, including immunotherapy, chemotherapy, and novel combinations. Through integrated patient case discussions, the session will highlight how molecular profiling drives...

Minimal Residual Disease (MRD) testing using circulating tumor DNA (ctDNA) has emerged as a promising tool for improving the management of gynecologic malignancies, including endometrial, ovarian, and cervical cancers. This 90-minute course explores the evolving role of ctDNA in identifying disease recurrence and assessing treatment response—potentially earlier than imaging or traditional biomarke...

This educational program offers a comprehensive and clinically relevant exploration of the rapidly evolving endometrial cancer treatment landscape, with a particular focus understanding the dynamic and evolving competitive landscape. The curriculum is designed to address the need for deeper clarity around differences in trial design, key efficacy outcomes, and therapeutic positioning.   Through a...

This educational session explores the evolving global landscape of advanced and recurrent cervical cancer, with a focus on disparities in access to care and treatment innovations. Participants will review pivotal clinical trial data shaping current treatment paradigms, including the role of antibody-drug conjugates (ADCs) as a novel therapeutic option. Emphasis will be placed on how to compare and...

While antibody-drug conjugates (ADCs) have reshaped therapeutic paradigms, the latest clinical trial results reveal a broader array of opportunities, spanning novel mechanisms of action, immunotherapy-based combinations, and molecularly targeted strategies. Through rigorous analysis of newly presented efficacy and safety data, including key PFS/OS endpoints, expert faculty will provide context and...

This symposium will explore the rapidly evolving landscape of treatment for recurrent low-grade serous ovarian cancer (LGSOC), with a focus on newly FDA-approved therapies and investigational strategies, MEC Inhibitors, CDK46 Inhibitors, hormonal treatments and other opportunities in the competitive landscape. LGSOC remains a challenging subtype due to its unique biology and resistance to conventi...